ACE-031 Study Terminated: Update From Acceleron and Shire

Acceleron and Shire are terminating a safety study of ACE-031, a drug aimed at Duchenne’s Muscular Dystrophy (and tested preclinically for ALS). During early clinical trials, the drug led to some minor bleeding and the study has since been halted. Acceleron and Shire have stated they remain committed to DMD research despite the setback.

Click here to read more.

Share this:
Facebooktwittergoogle_plusmailFacebooktwittergoogle_plusmail